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1University of Copenhagen, Nephrological Department B, Herlev Hospital, Herlev, Denmark; 2University of Copenhagen, Nephrological
Department P, Rigshospitalet, Copenhagen, Denmark; and 3Gubra, Hoersholm, DenmarkFibroblast growth factor 23 (FGF23) secreted by
osteocytes is a circulating factor essential for phosphate
homeostasis. High plasma FGF23 levels are associated with
cardiovascular complications and mortality. Increases of
plasma FGF23 in uremia antedate high levels of phosphate,
suggesting a disrupted feedback regulatory loop or an
extra-skeletal source of this phosphatonin. Since induction
of FGF23 expression in injured organs has been reported
we decided to examine the regulation of FGF23 gene and
protein expressions in the kidney and whether kidney-
derived FGF23 contributes to the high plasma levels of
FGF23 in uremia. FGF23 mRNA was not detected in normal
kidneys, but was clearly demonstrated in injured kidneys,
already after four hours in obstructive nephropathy and at
8 weeks in the remnant kidney of 5/6 nephrectomized rats.
No renal extraction was found in uremic rats in contrast to
normal rats. Removal of the remnant kidney had no effect
on plasma FGF23 levels. Well-known regulators of FGF23
expression in bone, such as parathyroid hormone, calcitriol,
and inhibition of the FGF receptor by PD173074, had no
impact on kidney expression of FGF23. Thus, the only direct
contribution of the injured kidney to circulating FGF23
levels in uremia appears to be reduced renal extraction
of bone-derived FGF23. Kidney-derived FGF23 does not
generate high plasma FGF23 levels in uremia and is
regulated differently than the corresponding regulation
of FGF23 gene expression in bone.
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Kidney International (2017) 92, 165–178P atients with chronic kidney disease (CKD) develop veryhigh plasma levels of ﬁbroblast growth factor 23(FGF23), an early and important component of their
disturbed mineral and bone disorder (MBD).1–3 A large
increase in FGF23 is an important factor associated with high
risk of morbidity and mortality.4–7 Still, the mechanisms
initiating and maintaining the high plasma levels of FGF23 in
CKD are poorly understood,8–11 and excessive secretion of
FGF23 by the injured kidney has been suggested.12,13
FGF23 is a 32-kDa glycoprotein that activates the
ﬁbroblast growth factor receptor (FGFR) in the presence of
the required coreceptor aKlotho.11,14 FGF23 decreases the
type II sodium–dependent phosphate (P) cotransporters
NaPi2a and NaPi2c in the proximal tubule of the kidney
and thereby inhibits P reabsorption.15–18 Furthermore,
FGF23 reduces 1,25-dihydroxy vitamin D (1,25vitD)
levels by inhibition of the 25-(OH)vitD 1-a-hydroxylase
Cyp27b1 and stimulation of the 1,25vitD 24-hydroxylase
Cyp24a1.19–21 FGF23 is part of the complex endocrine
network maintaining Ca2þ and P homeostasis, and
classical negative feedback loops have been demonstrated
between FGF23, 1,25vitD, and parathyroid hormone
(PTH).19,20,22,23 FGF23 is also regulated by FGFR1-
dependent signaling and local factors in bone.24–27
It is currently believed that osteoblasts and osteocytes are
the major source of circulating FGF23.28–30 However, recent
evidence has partially challenged this view because condi-
tional ablation of FGF23 in bone cells resulted in moderate
reduction in circulating FGF23 levels; therefore, other cellular
sources may contribute to circulating FGF23.31,32 Further-
more, the FGF23 increase in uremia antedate high plasma
levels of P, suggesting a disrupted feedback regulatory loop or
an extraskeletal source of this phosphatonin.1,13 The kidney
has been proposed as an extraskeletal source of FGF23,
because induced expression of FGF23 has recently been
demonstrated in injured kidney models of CKD.12,13,33
The purpose of the present experimental study was to
examine whether kidney-derived FGF23 contributes to the
high plasma levels of FGF23 in CKD. This was undertaken by
studying the expression of FGF23 induced in the kidney
rudiment of the 5/6 nephrectomy CKD model and in the
kidney of a short-term obstructive nephropathy model. The
impact of known regulators of FGF23 expression in bone,
such as calcitriol, PTH, dietary P load, and FGFR signaling165
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bas i c re sea r ch ML Mace et al.: Impact of kidney-derived FGF23 in uremiawas also examined for potential impact on the regulation of
FGF23 expression levels in the injured kidney.
RESULTS
Group characteristics
Long-term uremia was induced by 5/6 nephrectomy, and the
uremic rats were examined after 8 weeks and compared with
age-matched control rats. A subgroup of the uremic rats
had their parathyroid glands removed (PTX-uremic rats).
Biochemistry of all groups is shown in Table 1.
Induction and regulation of FGF23 expression in the kidney
in uremia
The kidney rudiment of the 5/6 nephrectomy model was
examined after 8 weeks of uremia. FGF23 gene expression was
not detected in kidneys of control rats with normal kidney
function, including control rats given calcitriol (Figure 1a).
On the contrary, FGF23 mRNA was clearly detected in kid-
neys of all uremic rats fed a standard or high-phosphate (HP)
diet. The presence of FGF23 protein was conﬁrmed by
Western blot, with signiﬁcantly higher protein levels in ure-
mic HP rats (P < 0.05) (Figure 1b and c). The injured kid-
ney’s FGF23 expression was not further stimulated by
calcitriol (Figure 1a). However, calcitriol affected the endog-
enous 1,25vitD regulation by a signiﬁcant downregulation of
the synthesis enzyme Cyp27b1 and upregulation of the
degradation enzyme Cyp24a1 (P < 0.05) (Figure 2h and i).
An HP diet strongly stimulated the kidney’s FGF23 expression
in uremic rats (P < 0.01) (Figure 1a). It should, however, be
noted that the HP diet also caused more severe kidney disease
(Table 1). Uremic HP-diet rats had lower expression levels
of the genes coding for the proteins constituting the FGF23
receptor complex FGFR1 IIIc and aKlotho and the phosphate
cotransporters NaPi2a and NaPi2c (P < 0.01) compared with
uremic standard-diet rats and control rats (Figure 2a–g and j).
There was no difference in expression of these genes in ure-
mic standard-diet rats and control rats. Cyp27b1 expression
was strongly upregulated in uremic HP-diet rats (Figure 2h),
consistent with our previous observation of normal circu-
lating calcitriol levels in this model of long-term uremia.34
Cyp27b1 was similarly expressed in uremic standard-diet
and control rats, along with same Cyp24a1 expression levels
(Figure 2h and i).
Importance of PTH in the regulation of FGF23 gene expression
in the kidney and bone in uremia
The effect of PTH signaling on the regulation of FGF23 gene
expression in kidney and bone was examined in rats that
underwent combined parathyroidectomy and 5/6 nephrec-
tomy (PTX-uremic).35 Expression of FGF23 was induced in
the kidney rudiment of PTX-uremic rats to a similar extent as
in uremic rats (Figure 3a). Expression of FGF23 was found in
all bone samples, where its relative expression was higher than
in the injured kidney. The uremic rats had higher bone FGF23
mRNA and plasma FGF23 levels compared with levels in
PTX-uremic rats (P < 0.05) (Figure 3b, Table 1). The166 Kidney International (2017) 92, 165–178
Figure 1 | Kidney ﬁbroblast growth factor 23 (FGF23) mRNA and protein in control and uremic rats. The effect of high dietary phosphate
load and calcitriol. (a) FGF23 mRNA was not detected in the normal kidneys of control rats or in control rats given calcitriol (þC). FGF23 mRNA
was detected in the kidneys of all uremic rats. Uremic rats on a high-phosphate (HP) diet had signiﬁcantly increased levels of kidney FGF23
mRNA (**P < 0.01). Kidney FGF23 mRNA levels were not further stimulated by calcitriol in uremic rats fed a standard diet (SD) or in uremic rats
fed an HP diet. FGF23 mRNA is shown as the ratio to the mean of reference genes actin, B2M, and GAPDH. In all groups, n ¼ 5. (b) A quantitative
analysis of the Western blot of kidney FGF23 protein (n ¼ 3; *P < 0.05). (c) Kidney FGF23 protein shown on a representative Western blot
with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a reference protein and recombinant FGF23 (R ¼ rFGF23) as a positive control;
C, control; U, uremic HP. The kidney protein from uremic rats was run in duplicates. Note that rFGF23 is a 25,5 kDa protein containing 228 AA
residues. To optimize viewing of this image, please see the online version of this article at www.kidney-international.org.
ML Mace et al.: Impact of kidney-derived FGF23 in uremia ba s i c re sea r chcoreceptor aKlotho was similarly downregulated in both
uremic groups (Supplementary Figure S1) but was not
detected in bone (data not shown).
Plasma levels of intact FGF23 in the renal artery and vein
In order to examine whether kidney-derived FGF23 con-
tributes to the high circulating level of FGF23 in uremia, the
concentration of intact FGF23 (iFGF23) was measured in the
renal artery and vein. Control rats had a renal iFGF23
extraction ratio of 0.31  0.04 (Figure 4a). No renal extrac-
tion of iFGF23 was found in uremic rats, and we did not ﬁnd
higher iFGF23 levels in the renal vein of uremic rats
compared with the renal artery (Figure 4a). To study the
importance of the kidney in FGF23 metabolism, acute uni-
lateral nephrectomy (UNX) was performed in normal rats,
resulting in an immediate, large iFGF23 rise (P < 0.05).
Excision of the kidney rudiment of uremic rats had no effect
on the high plasma iFGF23 levels, especially no decrease in
plasma iFGF23 after nephrectomy was found (Figure 4b).
FGF receptor signaling
The inﬂuence of FGFR signaling was examined using a high
dose of the FGFR inhibitor (FGFRi) PD173074, which within
5 hours gradually decreased plasma iFGF23 levels to
approximately one-third of baseline in both uremic and
normal rats (P < 0.01) (Figure 5a). Despite stable plasmaKidney International (2017) 92, 165–178Ca2þ and P in all groups during the study (Supplementary
Table S1), FGFRi caused a large increase in PTH levels in
both control and uremic rats (P < 0.05 and P < 0.01)
(Figure 5b). FGFRi resulted in not only a suppression of
plasma iFGF23, but also a downregulation of the bone’s
FGF23 expression in both uremic and normal control rats
(P < 0.001) (Figure 5c). FGF23 expression in the kidney
remained similar in both FGFRi- and vehicle-treated uremic
rats (Figure 5d). The acute administration of FGFRi increased
the expression levels of aKlotho mRNA and protein
(Figure 6a–c) and concomitantly increased NaPi2a and
NaPi2c mRNA in normal rats (P < 0.05), whereas it had no
effect on these genes in uremic rats (Figure 6g–j). The protein
expression of NaPi2a was not affected by FGFRi (Figure 6h
and i). This might be due to the short observation time or to
the rapid phosphaturic effect of PTH. Lower plasma levels of
Klotho were found in uremic rats. Plasma Klotho was not
affected by FGFRi (Figure 6d). FGFRi affected the enzymes
involved in 1,25vitD metabolism in both normal and uremic
rats, increasing Cyp27 and decreasing Cyp24 mRNA
(Figure 6e and f).
Kidney FGF23 correlates to the degree of ﬁbrosis
The kidney FGF23 mRNA levels were negatively associated
with gene expressions of the kidney protective markers
aKlotho and BMP7, and positively associated with the167
Figure 2 | The effect of chronic uremia, calcitriol, and a high-phosphate (HP) diet on kidney expression of the ﬁbroblast growth factor
23 (FGF23) receptor complex and FGF23 target genes. (a) The same expression levels of aKlotho mRNA were found in control and uremic
standard-diet (SD) rats, whereas they were reduced in the uremic HP rats (**P < 0.01 vs. sham and uremic SD). (b) Kidney Klotho protein shown
on a representative Western blot with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as a reference protein, and (c) a quantitative
analysis of the Western blot of kidney Klotho protein. Similar to the lower Klotho mRNA levels, the protein levels were reduced in the uremic HP
rats (control n ¼ 5, uremic n ¼ 6; *P < 0.05). (d) The sodium-dependent phosphate cotransporter NaPi2a gene was expressed at the same level
in control and uremic SD rats but signiﬁcantly decreased in uremic HP rats (**P < 0.01 vs. control and uremic). (e) NaPi2a protein is shown on a
representative Western blot with GAPDH as a reference protein. (f) A quantitative analysis of the Western blot shows a signiﬁcant (Continued)
bas i c re sea r ch ML Mace et al.: Impact of kidney-derived FGF23 in uremia
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Figure 3 | Gene expressions of ﬁbroblast growth factor 23 (FGF23) in kidney and bone of normal, uremic, and parathyroidectomized
(PTX) and uremic rats. (a) No expression of FGF23 was detected in the kidneys of control rats, whereas similar signiﬁcantly elevated levels of
FGF23 mRNA were found in both uremic and PTX-uremic rats. The relative level of FGF23 mRNA was lower in (a) the kidney than in (b) bone. (b)
Expression of FGF23 was found in all bone samples. The level of FGF23 mRNA was higher in the bone of uremic rats compared with the PTX-
uremic rats (*P < 0.05). FGF23 mRNA is shown as the ratio to the mean of reference genes actin, B2M, Arbp, EEF1A1, and GAPDH. Control and
uremic rats n ¼ 6; PTX-uremic rats n ¼ 3.
ML Mace et al.: Impact of kidney-derived FGF23 in uremia ba s i c re sea r chﬁbrosis markers periostin and TGF1b (Supplementary
Figures S2 and S3).
Expression of FGF23 detected in obstructive nephropathy
In order to examine whether FGF23 was expressed in the
injured kidney tissue in the absence of severe mineral de-
rangements and systemic effects of chronic kidney failure,
unilateral ureter obstruction (UUO) was performed. Inter-
estingly, minor levels of FGF23 mRNA were already detected
after 2 hours of obstruction, with a further signiﬁcant increase
at 4 and 6 hours (Figure 7a). The increased levels persisted for
10 days in the obstructed kidney. FGF23 mRNA was not
detected in the contralateral kidney or in the remaining
kidney after UNX (Figure 8). Plasma levels of iFGF23
increased signiﬁcantly after 2 hours of UUO (P < 0.05)
(Figure 7) and remained at a higher level for 10 days of
observation time (Figure 8). A similar plasma FGF23 increase
was found after UNX (Figure 8b). Bone FGF23 mRNA levels
were similar among all groups (Figure 8c). There was no
change in the expression levels of aKlotho and phosphate
transporters for up to 6-hour UUO, but these became
downregulated after 1 day of obstruction (Figure 7b–d).
Localization of renal FGF23 mRNA by in situ hybridization
In situ hybridization was performed in order to illustrate
which cells were expressing FGF23 in the kidney. In both
the obstructed kidneys and the kidney rudiments of long-
term uremic rats, cells within the interstitial space were
expressing FGF23 mRNA. In 6-hour UUO, positive FGF23=
Figure 2 | (Continued) decrease of NaPi2a protein in the kidneys of urem
dependent phosphate cotransporter NaPi2c gene was expressed at the
in uremic HP rats (**P < 0.01 vs. control and uremic). (h) Similar expres
These levels were, however, signiﬁcantly suppressed by calcitriol (þC) (*
signiﬁcantly higher levels of Cyp27b1 (**P < 0.01 vs. control and uremic S
vs. untreated group). (i) Similar levels of Cyp24a1 were found in control, u
by calcitriol in control and uremic SD rats (*P < 0.01). (j) The same leve
were reduced in the uremic HP rats (**P < 0.01 vs. control and uremic S
actin, B2M, Arbp, and EEF1A1 (n ¼ 5 in all groups). To optimize viewing of
international.org.
Kidney International (2017) 92, 165–178cells were found in the cortex, medulla, and papilla (Figure 9),
which supported the high expression levels found by poly-
merase chain reaction (Figure 7). The results of immuno-
histochemistry are discussed in the Supplementary Figure S5.
DISCUSSION
In the present study we demonstrated signiﬁcant expression
of FGF23 in the injured kidney tissue of the 5/6 nephrectomy
CKD model and in obstructive nephropathy in rats. Mea-
surements of iFGF23 in the renal artery and vein demon-
strated that kidney-derived FGF23 is not generating the high
plasma levels of iFGF23 in uremia. The relative gene
expression of FGF23 was lower in the kidney compared with
bone, supporting the notion of bone being the primary source
of FGF23 in CKD. The well-known stimulators of FGF23
expression in bone such as 1,25vitD and PTH did not affect
the regulation of FGF23 gene expression in the injured kidney.
Inhibition of the FGF receptor resulted in a downregulation
of bone FGF23, but it had no effect on the kidney’s FGF23
gene expression. A high dietary P load was, however, associ-
ated with signiﬁcantly increased kidney FGF23 expression,
although these rats also became more uremic and had further
increased markers of ﬁbrosis.
We have previously demonstrated a signiﬁcant extraction
of FGF23 in the normal kidney and a short half-life of
FGF23 of 4 minutes in normal rats.10 In the kidney rudiment
of the uremic rat no extraction of FGF23 was found, sup-
porting our earlier ﬁndings of a signiﬁcant prolonged half-life
of FGF23 after bilateral nephrectomy and illustrating anic HP rats (*P < 0.05). Control n ¼ 5; uremic n ¼ 6. (g) The sodium-
same level in control and uremic SD rats but signiﬁcantly decreased
sion levels of Cyp27b1 were found in control and uremic SD rats.
P < 0.05, ** P < 0.01, vs. untreated groups). Uremic HP rats had
D), and these were also signiﬁcantly suppressed by calcitriol (*P < 0.05
remic SD, and uremic HP rats, and these were signiﬁcantly stimulated
ls of FGFR1IIIc were found in control and uremic SD rats, but these
D). All mRNAs are shown as the ratio to the mean of reference genes
this image, please see the online version of this article at www.kidney-
169
Figure 4 | Plasma levels of intact ﬁbroblast growth factor 23
(FGF23) in the renal artery and vein of normal and uremic rats,
and circulating FGF23 levels before and after acute nephrectomy.
(a) Concentration of intact FGF23 (iFGF23) in the renal artery and
isolated renal vein of long-term uremic rats and age-matched control
rats. Control rats had a signiﬁcant difference in iFGF23 levels between
the renal artery and vein, with a 0.31  0.04 renal extraction ratio
(**P < 0.01). In uremic rats the iFGF23 levels were signiﬁcantly higher
(P < 0.01), but no signiﬁcant renal extraction was found (uremic
rats n ¼ 9; control rats n ¼ 6). (b) The effect of acute unilateral
nephrectomy (UNX) in control rats or removal of the kidney rudiment
(NX) in the uremic rats on iFGF23 levels. Acute UNX in control rats
resulted in an immediate signiﬁcant increase in iFGF23 (**P < 0.01)
15 minutes after UNX. NX in uremic rats did not change the plasma
levels of iFGF23. Control and uremic rats n ¼ 6.
bas i c re sea r ch ML Mace et al.: Impact of kidney-derived FGF23 in uremiaessential function of the kidney in FGF23 metabolism.10 The
increase in plasma FGF23 levels after ureter obstruction
underlines the impact of renal extraction of the hormone on
its circulating levels. Noticeably, FGF23 levels were not higher
in the renal vein compared with the renal artery in uremic
rats, as would have been expected if the kidney were a major
contributor to circulating levels. Even though the uremic and
PTX-uremic rats had the same expression of FGF23 in their
injured kidneys, the PTX-uremic rats had the same plasma170FGF23 levels as control rats. Uremic rats had ten-fold
higher plasma FGF23, and removal of the remnant kidney
tissue did not result in a drop in FGF23 plasma. Collectively,
these results illustrate that kidney-derived FGF23 is not
contributing signiﬁcantly to the high plasma levels of FGF23
in uremia.
Although signiﬁcant FGF23 expression in injured kidney
has been reported by different investigators,12,33 the intrarenal
localization of FGF23 is still controversial. In the present
study, in situ hybridization clearly demonstrated that the main
sites of FGF23 mRNA were exclusively in cells within the
interstitial space of both the obstructed kidney and kidney
rudiment of uremic rats. This is in contrast to other in-
vestigations reporting that FGF23 protein was predominantly
expressed in tubular cells by immunostaining. Zanchi et al.
found focal expression of FGF23 in both proximal and
distal tubulus cells in a model of diabetic nephropathy.33
Expression of FGF23 was detected when the rats had devel-
oped proteinuria and early kidney injury but did not coincide
with higher plasma levels of FGF23.33 Spichtig et al. described
expression of FGF23 in the cells lining the cysts in a mouse
model and in a rat model of polycystic kidney disease before a
rise in plasma creatinine and urea. This was associated with
an increase in plasma FGF23, while FGF23 mRNA levels in
bone remained unchanged.12 We demonstrated FGF23 pro-
tein using Western blot and found signiﬁcant bands in the
kidney tissue of uremic rats and no or minimal protein
detected in control rats. The latter could be due to FGF23
protein in capillaries and bound in receptors. We also
demonstrated a very early expression of kidney FGF23 gene at
4 and 6 hours of obstructive nephropathy. Collectively, all
studies illustrate that the injured kidney expresses FGF23
regardless of the kidney disease model. Further investigations
are needed to better characterize these cells localized in the
interstitial space expressing FGF23.
Similar expression of FGF23 was found in the injured
kidneys of PTX-uremic rats and uremic rats with intact
parathyroids. There was no increase in iFGF23 plasma levels
and bone expression in PTX-uremic rats. Lavi-Moshayoff
et al. have previously demonstrated an important impact of
hyperparathyroidism on the development of the high levels of
FGF23 in uremia.23 In the present investigation we found no
impact of PTH on the kidney’s FGF23 expression. 1,25vitD is
a strong stimulus for FGF23 expression in bone.19,20 In the
present study no effect of calcitriol was found on the kidney’s
FGF23 expression, although it cannot be excluded that cal-
citriol administration might affect kidney FGF23 via its
impact on endogenous 1,25vitD metabolism. As such, our
results demonstrate that kidney FGF23 is expressed inde-
pendently of the classical regulatory feedback loops.
FGFR1 signaling has emerged as an important pathway by
which FGF23 is regulated in bone.10,24,26,27 In the present
investigation, inhibition of the FGF receptor resulted already
after 5 hours in a suppression of FGF23 expression in bone in
both control and uremic rats, along with decreased plasma
levels. In contrast to this effect on bone, FGFRi had no effectKidney International (2017) 92, 165–178
Figure 5 | Effect of ﬁbroblast growth factor receptor inhibition (FGFRi) on plasma levels of intact ﬁbroblast growth factor 23 (p-iFGF23)
and parathyroid hormone (p-PTH), and on the gene expression of FGF23 in bone and kidney in normal and uremic rats. (a) The p-iFGF23
after a single 20-mg dose of PD173074, the pharmacological FGF receptor inhibitor (FGFRi), or vehicle administered at 0 hours (h). FGFRi
signiﬁcantly decreased the p-iFGF23 level after 5 hours to one-third of baseline values in both control and uremic rats (**P < 0.01). The p-iFGF23
levels were stable in the vehicle-treated groups. (b) FGFRi resulted in a signiﬁcantly large increase in p-PTH in both control and uremic rats
(*P < 0.05, **P < 0.01, vs. vehicle groups) as measured after 5 hours. PTH remained stable in vehicle groups. Plasma Ca2þ and P remained
stable during the study in all groups (Supplementary Table S1). (c) FGFRi suppressed FGF23 expression in bone in both control and uremic
rats (***P < 0.001 vs. vehicle). (d) No expression of FGF23 was detected in the kidneys of control rats. Similar levels of kidney FGF23 mRNA were
found in uremic rats treated with vehicle versus FGFRi. Kidney FGF23 mRNA is shown as the ratio to the mean of reference genes B2M, EEF1A1,
and Arbp. Bone FGF23 mRNA is shown as the ratio to the mean of reference genes GAPDH and EEF1A1. Control vehicle and FGFRi n ¼ 6, uremic
vehicle n ¼ 8, and uremic FGFRi n ¼ 10.
ML Mace et al.: Impact of kidney-derived FGF23 in uremia ba s i c re sea r chon the kidney’s expression of FGF23, demonstrating again
that the kidney’s expression of FGF23 is not regulated in a
manner similar to the corresponding expression in bone.
It was shown that FGFRi, despite stable Ca2þ and
P, triggered a large increase in PTH in both control and
uremic rats. This could be explained by abolition of a sup-
pressive tonus of FGF23 on the parathyroids,36 although this
would be in contrast to the notion of parathyroid resistance
to FGF23 in uremia.37–39 Our results demonstrate a relative
renal resistance to FGF23 in uremia, as FGFRi did not in-
crease aKlotho, NaPi2a, and NaPi2c expression in uremic rats
in contrast to the increase seen in normal rats. FGFR1 and
perhaps FGFR4 have key roles in FGF23 bioactivity in the
kidney.14 Thus, the lack of response of NaPi2a and NaPi2c
expression to FGFRi in uremic rats might be due to the fact
that FGFR1 expression was already decreased in advance, as
shown in our results.Kidney International (2017) 92, 165–178The demonstration in the present study of an increased
expression of aKlotho in the kidney of FGFRi rats is novel. In
another investigation of transgenic mice overexpressing
FGF23, renal aKlotho was the most decreased transcript,
which together with our results indicates an impact of the
FGF23-FGFR pathway on Klotho regulation in the kidney.40
This is in accordance to conditions described in the para-
thyroid, where FGF23 was found to inhibit aKlotho mRNA.36
A high phosphate load stimulated FGF23 expression in the
injured kidney, plausibly an adaptive mechanism in response
to higher phosphate ﬁltration in the functioning nephrons.
We were, however, unable to differentiate between a possible
adaptive response and a cytotoxic effect of phosphate over-
load, because the uremic HP rats suffered from more severe
uremia with signiﬁcant downregulation of the FGF23 receptor
complex and target genes compared with uremic SD rats.
Present results clearly showed expression of the FGF23 gene171
Figure 6 | Effect of ﬁbroblast growth factor receptor inhibition (FGFRi) on the expression of ﬁbroblast growth factor 23 (FGF23)
coreceptor Klotho and FGF23 target genes in kidneys of normal and uremic rats. The FGFR inhibitor (FGFRi) PD173074 or the vehicle was
administered to control and uremic rats. (a) The uremic rats had lower expression of aKlotho versus control rats (*P < 0.05). FGFRi increased the
expression levels of aKlotho in normal rats (*P< 0.05) but had no effect on aKlotho levels in uremic rats. (b) Western blot showing kidney Klotho
protein expression in control rats given vehicle or FGFRi. A quantitative analysis of the Western blot showed that FGFRi increased the expression
levels of Klotho protein in normal rats (n ¼ 5 vehicle, n ¼ 6 FGFRi; *P < 0.05). (c) Western blot showing kidney Klotho protein expression in
uremic rats given vehicle or FGFRi. A quantitative analysis showed that FGFRi had no effect on levels of Klotho protein in uremic rats (n ¼ 5
vehicle, n ¼ 6 FGFRi). (d) Plasma Klotho levels were signiﬁcantly lower (*P < 0.05) in uremic rats but were not affected by FGFRi in these short-
duration experiments. (e,f) FGFRi upregulated Cyp27b1 gene expression in both control and uremic rats (**P < 0.01), whereas Cyp24a1 gene
expression was signiﬁcantly downregulated in both uremic and control rat kidneys (*P < 0.05; **P < 0.01). (g,j) The sodium-dependent
phosphate cotransporter NaPi2a and NaPi2c genes were downregulated in uremic rats compared with the control group (*P < 0.05). FGFRi
increased the expression levels of NaPi2a and NaPi2c in normal rats but had no effect on these genes in uremic rats. (h,i) In contrast to the gene
expression, the protein levels in both control and uremic rat kidneys were not affected by FGFRi. All mRNA levels are shown as the ratio to the
mean of reference genes B2M, Arbp, and EEF1A1. Control vehicle and FGFRi n ¼ 6, uremic vehicle n ¼ 8, and uremic FGFRi n ¼ 10. To optimize
viewing of this image, please see the online version of this article at www.kidney-international.org.
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Figure 7 | Expression of kidney FGF23, aKlotho, NaPi2a, and NaPi2c genes and plasma ﬁbroblast growth factor 23 (FGF23) levels in
early obstructive nephropathy. A unilateral ureter obstruction (UUO) model was used. (a) Normal kidney tissue had no detectable FGF23
gene expression. Minor FGF23 expression was detected after 2-hour (h) UUO, and signiﬁcant levels were detected at 4 h of UUO, with a further
increase at 6 h (*P< 0.001). (b–d) The expressions of kidney aKlotho, NaPi2a, and NaPi2c genes remained unchanged at 2, 4, and 6 h of UUO but
decreased signiﬁcantly (*P < 0.01) after 24 h of obstruction. (e) Plasma FGF23 increased signiﬁcantly (*P < 0.05) after 2-h UUO to the level we
have previously shown in a single-kidney rat model.10 Kidney FGF23 mRNA is shown as the ratio to reference genes actin, B2M, and TBP. Kidney
aKlotho, NaPi2a, and NaPi2c are shown as the ratio to baseline (set to 1); n ¼ 6 in each group.
ML Mace et al.: Impact of kidney-derived FGF23 in uremia ba s i c re sea r chearly in the obstructive nephropathy model, but this increase
was not associated with any change in NaPi2a and NaPi2c,
and therefore these data do not point toward a direct effect of
renal FGF23 on phosphate excretion. Because FGF23-
expressing cells were located in the interstitium, this further
supports no direct relation to FGF23-dependent enzyme and
transporters. Furthermore, regulators of renal phosphate
excretion and calcitriol homeostasis such as PTH, FGF23, and
calcitriol did not regulate renal FGF23 expression. Collec-
tively, these results do not support the notion of renal FGF23
having a direct effect on phosphate transporters or calcitriol
regulating enzymes. The kidney’s expression level of FGF23
correlated with the degree of ﬁbrosis based on expression of
periostin,41,42 and correlated negatively with the kidney pro-
tecting factors BMP7 and aKlotho.43–45 It therefore seems
likely that the kidney’s expression of FGF23 increases with
progression of renal ﬁbrosis, but whether FGF23 plays a roleKidney International (2017) 92, 165–178in regeneration or in a proﬁbrotic process remains to be
established.
Induction of FGF23 expression might take place in other
injured organs as well as in tumors.46 Ischemia of the heart
resulted in an increased expression of FGF23 in car-
diomyocytes47 and cardiac ﬁbroblast cells.48 Expression of
FGF23 in injured liver tissue coincided with higher plasma
FGF23.49 FGF23 is expressed in both heart and liver during
embryogenesis up to week 8.50 FGF9 and FGF20 play an
important role in nephrogenesis,50,51 whereas FGF23 expres-
sion was not found in the developing zebraﬁsh kidney.52
FGF23 belongs to the family of ﬁbroblast growth factors, in
which the majority of proteins regulate embryogenesis, growth,
and angiogenesis and play an important role in organ regen-
eration and repair.53 Whether kidney-derived FGF23 has an
autocrine or paracrine function in the renal repair system
merits further study. Inﬂammatory activation of macrophages173
Figure 8 | Expression of ﬁbroblast growth factor 23 (FGF23) in
obstructive nephropathy. (a) No kidney FGF23 mRNA was detected
in the normal control kidney, in the contralateral kidney (data not
shown) in the model of unilateral ureter obstruction (UUO), or in the
remaining kidney of unilaterally nephrectomized (UNX) rats day 1 to
day 10. In the obstructed kidney, FGF23 mRNA was detected at day 1
of ureter obstruction. (b) The plasma levels of intact FGF23 (iFGF23)
were signiﬁcantly increased at day 1 in UUO rats and remained at a
higher level. A similar signiﬁcant increase in plasma iFGF23 was found
in the control model of UNX rats (*P < 0.05 vs. baseline). (c) Bone
FGF23 mRNA levels were similar among all groups. This indicates the
importance of renal extraction of FGF23 on the plasma levels. Kidney
FGF23 mRNA expression levels are shown as the ratio to the mean of
reference genes actin, B2M, and TBP. Bone FGF23 mRNA expression
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174and bone marrow dendritic cells induce expression of FGF23,
and FGF23 has been shown to stimulate expression of tumor
necrosis factor alpha in a macrophage cell line.54 The mecha-
nisms inducing FGF23 expression and its function in these cells
and injured tissues are unknown. Even though the phospha-
turic and 1,25vitD regulatory functions of FGF23 are clearly
established, additional functions of the protein in the inﬂam-
matory process are possible.54–56
In conclusion, FGF23mRNA is not expressed in the normal
kidney but is rapidly induced in injured kidneys. The regula-
tion of kidney FGF23 mRNA expression is different from that
of its corresponding expression in bone. Kidney-derived FGF23
is not generating the high FGF23 plasma levels in uremia.
METHODS
Animals
Adult male Wistar rats (Taconic A/S, Ejby, Denmark) were used in this
study. They were housed in a temperature-controlled environment
with a 12-hour light-dark cycle and free access to water and food. The
standard diet contained 0.9% Ca, 0.7% P, and 600 IU vitamin D3 per
kg food. The HP diet contained 0.9% Ca, 1.4% P, and 600 IU vitamin
D3 per kg food (Altromin, Lage, Germany). The biochemistry of rats
given calcitriol and HP has been described previously.37 In long-term
studies, all uremic rats were fed an HP diet.
Study approval
The experimental protocols were approved by the Danish Animal
Experiments Inspectorate (2012-DY-2934-00023/BES) and per-
formed in accordance with national guidelines.Experimental protocols
CKD was induced by 1-step 5/6 nephrectomy.5,57 Duration of
uremia was 8 weeks (renal artery and vein sampling were per-
formed after 14 weeks of uremia). UUO was performed by ligation
of the left ureter. UNX was performed by ligation of the renal vessel
and removal of the kidney.5 A group of rats had their parathyroid
glands removed by excision under stereomicroscope.9,35,58 Rats
were anesthetized with fentanyl/ﬂuanisone and midazolam for the
surgical procedures and received carprofen as pain relief. Pento-
barbital was used at killing.5
The renal artery was punctured close to its junction with the
aorta. The renal vein was punctured after prior ligation of the ad-
renal and testicular veins and clamping of the vena cava inferior.10
The aorta was punctured 15 minutes after UNX or NX.
A single 200-ng dose of calcitriol (Leo Pharma, Ballerup,
Denmark) was given i.p., and the kidney was harvested after
24 hours.37 The impact of FGFR signaling was studied using a single
20-mg dose of the pan-FGFR inhibitor PD173074 (LC Laboratories,
Woburn, MA) dissolved in 200 ml 96% ethanol administered by oral
gavage.
Biochemistry
Plasma Ca2þ was measured at actual pH by ABL 505 (Radiometer,
Brønshøj, Denmark). Plasma P, creatinine, and urea were analyzed by=
levels are shown as the ratio to the mean of reference genes B2M and
EEF1A1 (in all groups, 1- to 4-day UUO n ¼ 6, 10-day UUO n ¼ 7, and
10-day UNX n ¼ 5).
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Figure 9 | Fibroblast growth factor 23 (FGF23) in situ hybridization of kidney tissue from acute obstructed kidney, long-term uremic
rats, and control rats. The ﬁgure shows representative images from cortex, medulla, and papilla of the kidney. No FGF23 expression was
detected in any of the kidneys of control rats. FGF23 mRNA (red dots, arrowheads) was highly expressed in the injured kidney. It was exclusively
detected in the interstitial space. In the obstructed kidneys of unilateral ureteral obstruction (UUO) rats, FGF23 mRNA was found in the cortex,
medulla, and papilla at 6 hours after ureter obstruction. A similar interstitial distribution was observed in the cortex and medulla of the kidney
rudiments of all 5/6 nephrectomized (PNX) uremic rats, and no FGF23 mRNA expression was observed in the papilla. No FGF23 mRNA signal
was seen in the tubuli or in the glomeruli (n ¼ 3 in each group). To optimize viewing of this image, please see the online version of this article at
www.kidney-international.org.
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measured using rat bioactive intact PTH enzyme-linked immunosor-
bent assay (Immutopics, San Diego, CA). FGF23 was measured using
an intact FGF23 enzyme-linked immunosorbent assay (Kainos Labo-
ratories, Tokyo, Japan).59,60 Klotho plasma levels were measured by the
O’Brien Kidney Research Core Centre (University of Texas South-
western, Dallas, TX) using a synthetic Klotho antibody.61
Western blot
Protein was extracted using T-PER (Thermo Fisher Scientiﬁc,
Waltham, MA), and 50 mg of it was loaded on stain-free precast
Bio-Rad 4% to 15% gels, transferred onto nitrocellulose Bio-Rad
(Hercules, CA) membrane, and blocked in 5% bovine serum albu-
min in Tris-buffered saline with Tween 20 0.1% (Bio-Rad). PrimaryKidney International (2017) 92, 165–178FGF23 and Klotho antibody (AB56326, AB154163; Abcam, Cam-
bridge, UK) were diluted in 3% bovine serum albumin 1:1000.
NaPi2a (NBP2-13328; Novus Biologicals, Littleton, CO) 1:250 and
glyceraldehyde-3-phosphate dehydrogenase antibody (MAB374;
Merck Millipore, Billerica, MA) were diluted in milk 1:500. Secondary
antibodies were anti-goat, anti-rabbit and anti-mouse (P0160,
P0448, and P0447; Dako, Santa Clara, CA). Recombinant FGF23
(PeproTech, Rocky Hill, NJ) was used as a positive control. Quanti-
tative analysis was performed using AlphaEaseFC v.6 (Alpha Innotech,
San Leandro, CA).
Quantitative polymerase chain reaction
The kidney and femur (after removal of bone marrow) total RNA
were extracted using the EZNA RNA isolation kit (Omega Bio-tek,175
bas i c re sea r ch ML Mace et al.: Impact of kidney-derived FGF23 in uremiaNorcross, GA). Synthesis of cDNA was performed using Superscript
III (Invitrogen Corp, Waltham, MA). Roche LightCycler 480 (Roche,
Basel, Switzerland) was used with a temperature proﬁle of 94C for
2 minutes, 45 cycles of 94C for 30 seconds, 59C for 45 seconds,
and 72C for 90 seconds. The mRNA levels were normalized to the
mean of reference genes. Reference gene stability was conﬁrmed
using geNorm.62 Primers are listed in Supplementary Table S2.
In situ hybridization
Kidneys were ﬁxed in 10% neutral buffered formalin and embedded
in blocks of parafﬁn. In situ hybridization was carried out on 5-mm
thick kidney sections using the RNAscope 2.5 HD RED assay
(Advanced Cell Diagnostics, Hayward, CA) according to the man-
ufacturer’s instructions. FGF23 was detected with a rat-speciﬁc probe
against the sequence 9-652 of the mRNA (catalog no. 484501,
accession no. NM_130754.1). A probe against the housekeeping gene
peptidylprolyl isomerase B (catalog no. 313921, accession no.
NM_022536.2) was used as a positive control to verify mRNA quality
and assay procedures. A probe targeting the bacterial gene dapB
(catalog no. 310043, accession no. EF191515) was used as a negative
control.
Statistical analyses
Data are expressed as means  SEM or range. Statistical signiﬁcance
was tested using a 2-tailed t-test for data with normal distribution
and the Mann-Whitney U test as a nonparametric test. Linear
regression and curve ﬁtting was calculated in GraphPad Prism 4.0.
The signiﬁcance level was set at P # 0.05.
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SUPPLEMENTARY MATERIAL
Table S1. Plasma calcium2þ and phosphate levels at baseline and
5 hours after administration of FGF receptor inhibitior (FGFRi) or
vehicle in normal and uremic rats.
Table S2. Primers.
Figure S1. Expression of aKlotho mRNA in kidneys of uremic and
parathyroidectomized-uremic (PTX-uremic) rats compared with
control rats. The expression of aKlotho was signiﬁcantly reduced by
one-half in uremic rats (*P < 0.05). Similar levels of aKlotho mRNA
were found in uremic and PTX-uremic rats, despite a signiﬁcant
difference in circulating plasma levels of intact ﬁbroblast growth
factor 23 (FGF23) (Table 1). Furthermore, this reduction of aKlotho
expression in the kidney rudiment of the 5/6 nephrectomy model
was found despite increased expression of Cyp27b1 (Figure 2).
aKlotho mRNA is normalized to the mean of reference genes actin,
B2M, Arbp, EEF1A1, and GAPDH, and is shown as the relative expres-
sion to control group. Control and uremic rats n ¼ 6; PTX-uremic rats
n ¼ 3.
Figure S2. The expression levels of kidney ﬁbroblast growth factor 23
(FGF23) mRNA are plotted against the expression levels of renal
protective factors aKlotho and BMP7, and of ﬁbrosis markers periostin176and TGF1b. (A,B) The kidneys’ FGF23 expression levels were
negatively associated with the protective markers aKlotho and
BMP7. (C,D) The kidneys’ FGF23 expression levels were positively
associated with the ﬁbrosis markers periostin and TGF1b. The curve is
ﬁtted to the data. All uremic rats treated with calcitriol or vehicle
and fed a standard or high-phosphate diet were pooled in the ﬁgure
(n ¼ 18).
Figure S3. Linear correlations of kidney ﬁbroblast growth factor 23
(FGF23) mRNA expression and gene expression of renal protective
markers aKlotho and BMP7 and the ﬁbrosis marker periostin in
uremic rats. (A,B) The kidneys’ FGF23 expression was signiﬁcantly
negatively correlated to aKlotho (P < 0.01) and BMP7 (P < 0.05).
(C) The kidneys’ FGF23 expression was positively correlated to the
ﬁbrotic marker periostin (P < 0.05). Uremic ﬁbroblast growth factor
receptor inhibitor and uremic vehicle were pooled in the analysis
(n ¼ 18).
Figure S4. In situ hybridization with probes against ﬁbroblast
growth factor 23 (FGF23) and the bacterial gene dapB (negative
control) on adjacent kidney sections. The panel shows representative
images from the cortical region of the obstructed kidney of unilateral
ureteral obstruction (UUO) rats and the kidney rudiment of 5/6
nephrectomized uremic rats (PNX). FGF23 mRNA (arrowheads) was
located in between tubuli structures and sometimes lining the
luminal side of vessels. No in situ hybridization signal was detected
with the dapB probe, indicating that the assay was speciﬁc.
Figure S5. Fibroblast growth factor 23 (FGF23) immunostaining with
MyBioSource (San Diego, CA) MBS854462 antibody. Immunostaining
by the MyBioSource MBS854462 rabbit polyclonal antibody diluted
1:300 on kidney tissue from a normal control rat and the obstructed
kidney from unilateral ureteral obstruction (UUO) rats, after 6 hours of
ureter obstruction. (A–C) Proteinase K pre-treatment was used. (A) No
immunostaining was observed in kidney tissue obtained from normal
control rats. (B) No immunostaining was observed in the cortex,
(C) while immunoreactivity was observed in the collecting ducts of
the medulla in the obstructed kidney. However, when using a citrate
buffer and pH 6 as pre-treatment, only weak immunoreactivity was
observed in the distal tubuli (no brush border) in (D) the cortex and in
(E) the endothelium of vessel, (F) and no immunoreactivity was
observed in collecting ducts of the medulla. Immunostaining with the
Santa Cruz Biotechnology (Dallas, TX) sc-50291 rabbit polyclonal
antibody and Abcam (Cambridge, UK) ab56326 goat polyclonal
antibody did not result in any speciﬁc immunoreactivity (data not
shown). The observed immunostaining might therefore be consid-
ered as a potential fault.
Supplementary material is linked to the online version of the paper at
www.kidney-international.org.
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